341 related articles for article (PubMed ID: 29096156)
21. Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.
Shieh Y; Scott CG; Jensen MR; Norman AD; Bertrand KA; Pankratz VS; Brandt KR; Visscher DW; Shepherd JA; Tamimi RM; Vachon CM; Kerlikowske K
Breast Cancer Res; 2019 Apr; 21(1):48. PubMed ID: 30944014
[TBL] [Abstract][Full Text] [Related]
22. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
[TBL] [Abstract][Full Text] [Related]
23. Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer.
Scholz C; Andergassen U; Hepp P; Schindlbeck C; Friedl TW; Harbeck N; Kiechle M; Sommer H; Hauner H; Friese K; Rack B; Janni W
Breast Cancer Res Treat; 2015 Jun; 151(3):569-76. PubMed ID: 25962694
[TBL] [Abstract][Full Text] [Related]
24. Body mass index and prognosis of breast cancer: An analysis by menstruation status when breast cancer diagnosis.
Sun L; Zhu Y; Qian Q; Tang L
Medicine (Baltimore); 2018 Jun; 97(26):e11220. PubMed ID: 29952978
[TBL] [Abstract][Full Text] [Related]
25. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer.
Gabos Z; Thoms J; Ghosh S; Hanson J; Deschênes J; Sabri S; Abdulkarim B
Breast Cancer Res Treat; 2010 Nov; 124(1):187-94. PubMed ID: 20814819
[TBL] [Abstract][Full Text] [Related]
26. St. Gallen endocrine response classes predict recurrence rates over time.
Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
[TBL] [Abstract][Full Text] [Related]
27. Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence.
Bogina G; Lunardi G; Coati F; Zamboni G; Gori S; Bortesi L; Marconi M; Cassandrini PA; Turazza M; Cortesi L; DeMatteis E; Ficarra G; Ibrahim T; Serra P; Medri L; Giraudi S; Lambertini M; Carli F; Foglietta J; Sidoni A; Nunzi M; Ficorella C; Diadema MR; Del Mastro L
Tumori; 2015; 101(4):398-403. PubMed ID: 26045108
[TBL] [Abstract][Full Text] [Related]
28. Does obesity have an effect on outcomes in triple-negative breast cancer?
Mowad R; Chu QD; Li BD; Burton GV; Ampil FL; Kim RH
J Surg Res; 2013 Sep; 184(1):253-9. PubMed ID: 23768767
[TBL] [Abstract][Full Text] [Related]
29. Recurrence dynamics does not depend on the recurrence site.
Demicheli R; Biganzoli E; Boracchi P; Greco M; Retsky MW
Breast Cancer Res; 2008; 10(5):R83. PubMed ID: 18844974
[TBL] [Abstract][Full Text] [Related]
30. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Mansell J; Monypenny IJ; Skene AI; Abram P; Carpenter R; Gattuso JM; Wilson CR; Angerson WJ; Doughty JC
Breast Cancer Res Treat; 2009 Sep; 117(1):91-8. PubMed ID: 19112615
[TBL] [Abstract][Full Text] [Related]
31. Impact of the obesity on lymph node status in operable breast cancer patients.
Keskin O; Aksoy S; Babacan T; Sarici F; Kertmen N; Solak M; Turkoz FP; Arik Z; Esin E; Petekkaya I; Altundag K
J BUON; 2013; 18(4):824-30. PubMed ID: 24344004
[TBL] [Abstract][Full Text] [Related]
32. Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.
Desmedt C; Demicheli R; Fornili M; Bachir I; Duca M; Viglietti G; Berlière M; Piccart M; Sotiriou C; Sosnowski M; Forget P; Biganzoli E
J Natl Cancer Inst; 2018 Oct; 110(10):1115-1122. PubMed ID: 29718396
[TBL] [Abstract][Full Text] [Related]
33. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
34. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
Dignam JJ; Dukic V; Anderson SJ; Mamounas EP; Wickerham DL; Wolmark N
Breast Cancer Res Treat; 2009 Aug; 116(3):595-602. PubMed ID: 18830816
[TBL] [Abstract][Full Text] [Related]
35. The association between body mass index and immunohistochemical subtypes in breast cancer.
Sahin S; Erdem GU; Karatas F; Aytekin A; Sever AR; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():227-236. PubMed ID: 27756509
[TBL] [Abstract][Full Text] [Related]
36. Factors that predict recurrence later than 5 years after initial treatment in operable breast cancer.
Wangchinda P; Ithimakin S
World J Surg Oncol; 2016 Aug; 14(1):223. PubMed ID: 27557635
[TBL] [Abstract][Full Text] [Related]
37. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
38. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
[TBL] [Abstract][Full Text] [Related]
39. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
40. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
